Arkin Holdings

Investor type

PE

Last fund created

2008

AUM

-

Location

Israel

$0-1 m

Investment Ticket

3-5 years

Investment Horizon

Seed, Series B, Series A

Investment Stage

Sale to strategic investor, IPO

Exit Strategy

Profile

FAMILY HISTORY In 1961 Mr. Ziama Arkin founded Agis as the certified Israeli pharmaceutical importer for a number of foreign pharma companies. After the death of Mr. Ziama Arkin in 1972, his 19 year old son, Mori, took the lead, while he was serving in the IDF and completing a degree in Psychology. In 1994, Agis purchased Clay Park and gained with it, control over its first production facility. A new era of Agis drug development and production had begun. Under Mori Arkin, who remained the principal shareholder and chairman of the board, Agis (1983) Ltd. grew to become one of the biggest leaders in the dermatological generic space in the US. In 2005 Perrigo (PRGO) purchased Agis in an $818M transaction. Arkin Holdings is dedicated to empowering companies that create breakthrough pharma, biotech and medical device technologies. Our synergistic healthcare investments are dedicated to creating innovations that benefit humanity and enhance medical care. We offer extensive experience, with a track record of successful healthcare investments. Experts in the dynamic world of healthcare development, we provide the know-how and close accompaniment that helps our portfolio investments achieve substantial value and growth.

Industry

Education Edtech Healthcare Services Real Estate Robotics Transportation HealthTech

Region of investment

North America Europe

Contacts

Upgrade to see contacts
Name
Title
Email
avatar
nySjRB40JVzEwaug Investment Manager - Digital Health
Investment Manager - Digital Health
avatar
nySjRB40JVzEwaug Investment Manager
Investment Manager
avatar
nySjRB40JVzEwaug Biotech Analyst
Biotech Analyst
avatar
nySjRB40JVzEwaug Real Estate Investment Manager
Real Estate Investment Manager
avatar
nySjRB40JVzEwaug Investment Manager
Investment Manager
If there are no contacts of this investor, please write to us, we will try to find them as soon as possible and get back to you!